Comparison · NCT03279731-324dd71e
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: Remission From Binge-eating
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: Remission From Binge-eating. Trial comparisons, record NCT03279731-324dd71e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03279731-324dd71e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.429 | 0.158 | 0.75 | wilson | |
| Risk in group 2 | 0.5 | 0.215 | 0.785 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0714 | -0.464 | 0.358 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.857 | 0.285 | 2.58 | log | |
| Odds ratio, group 1 over group 2 | 0.75 | 0.0975 | 5.77 | log | |
| Number needed to treat, for one fewer participant with the outcome on Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml than on Placebo | 14 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml | Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.~Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. | 3 | 7 | OG000 |
| Group 2 | Placebo | Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.~Placebo: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection | 4 | 8 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Remission From Binge-eating
- Description
- the percentage of participants (completers) who have achieved remission from binge-eating (no binge episodes between weeks 13 - 17)
- Time frame
- 13 to 17 weeks
- Population
- Remission was calculated for completers who had data from weeks 13-17
Source ClinicalTrials.gov
Trial
- Title
- Binge Eating Liraglutide Intervention
- NCT number
- NCT03279731
- Phases
- PHASE3
- Conditions
- Binge-Eating Disorder
- Interventions
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml, Placebo
- Lead sponsor
- Kelly Allison
- Results first posted
- 2020-11-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03279731?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03279731-324dd71e